NCT05501821 - Study of KBA1412 in Participants With Advanced Solid Malignant Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

July 24, 2024

Study Completion Date

July 24, 2024

Conditions

Advanced Solid Tumor Malignancy

Interventions

DRUG

KBA1412

Part A, B, C

DRUG

Pembrolizumab

Part C only

Trial Locations (5)

University Hospital Antwerp, Antwerp

University Hospital Ghent, Ghent

Dutch Cancer Institute AVL, Amsterdam

University Hospital Leiden (LUMC), Leiden

Erasmus Medical Center Rotterdam, Rotterdam